Is Sermorelin Legal in South Carolina?

The Short Answer: Sermorelin Is Legal in South Carolina With a Prescription

Sermorelin does not appear on the FDA's list of bulk drug substances that may not be used in compounding, which means licensed 503A pharmacies can legally prepare it for individual patients when a valid prescription exists. South Carolina follows federal compounding law and does not impose additional state-level bans on sermorelin.

The legal pathway has specific requirements. The prescription must come from a practitioner with prescriptive authority in the state, the compounding pharmacy must hold a valid South Carolina Board of Pharmacy license, and the preparation must be patient-specific rather than manufactured in bulk for general sale. Skipping any of those steps moves the transaction into legally gray or outright illegal territory.

Why Sermorelin Is Not the Same as a Banned Peptide

Some growth hormone-related peptides have been placed on the FDA's "Category 2" bulks list, meaning compounding pharmacies cannot use them regardless of physician intent. Examples include CJC-1295, ipamorelin (as of certain FDA guidance periods), and BPC-157. Sermorelin has not been placed on that prohibited list as of this publication.

The FDA maintains a running list of bulk drug substances nominated for use in compounding at FDA 503A Bulks Nominations. Patients and providers should check this list periodically because the FDA can update its category designations without widespread public notice.

What "Legal" Does Not Mean Here

Legal availability through compounding is not the same as FDA approval. Sermorelin was briefly approved as a finished drug product under the brand name Geref (sermorelin acetate for injection), but Geref was withdrawn from the U.S. Market in 2008 for commercial reasons, not safety concerns. The withdrawal of a brand product does not prohibit compounding of the same active ingredient when the ingredient itself remains permissible under federal compounding statutes [Drug Information: Geref discontinuation, FDA records].

Federal Legal Framework: FDA 503A, 503B, and the Bulks List

Understanding sermorelin's legal status requires a working knowledge of two sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that govern pharmaceutical compounding in the United States.

Section 503A: Patient-Specific Compounding

503A is the pathway used by most independent compounding pharmacies. Under 503A, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription from a licensed practitioner FDA, Section 503A of the FD&C Act. The compounded preparation must not be a copy of a commercially available FDA-approved drug, and the bulk ingredient used must either appear on the FDA's 503A Bulks List (approved substances) or must not appear on the prohibited list.

Sermorelin currently falls into the permissible category. A 503A compounding pharmacy in South Carolina can legally prepare sermorelin acetate for injection when all the following conditions are met:

• A licensed South Carolina prescriber issues a patient-specific prescription.
• The pharmacy holds a valid South Carolina Board of Pharmacy compounding license.
• The bulk sermorelin acetate used meets USP or equivalent purity standards.
• The final preparation is not sold wholesale or distributed without a prescription.

Section 503B: Outsourcing Facilities

503B outsourcing facilities can compound larger quantities and distribute to healthcare facilities without patient-specific prescriptions, but they operate under stricter FDA oversight, including Current Good Manufacturing Practice (CGMP) requirements. A small number of 503B-registered facilities compound sermorelin for clinic dispensing. The FDA maintains the current list of registered 503B outsourcing facilities at FDA Registered Outsourcing Facilities.

If a South Carolina clinic sources sermorelin from a 503B facility, the product carries a higher manufacturing quality guarantee than 503A compounding, though both pathways are legally valid.

The Bulks List: The Critical Document to Watch

The FDA's 503A Bulks evaluation process sorts nominated substances into three categories. Category 1 substances are under evaluation. Category 2 substances are those for which the FDA has determined there are safety concerns or lack of clinical necessity, and Category 2 placement effectively prohibits compounding use. Sermorelin has not been placed in Category 2 as of this article's review date FDA Bulks Nominations, PubChem CID 16132827.

Because the regulatory picture can shift, every provider prescribing sermorelin in South Carolina should confirm current status before writing a prescription.

South Carolina State Law: What the Board of Pharmacy Requires

South Carolina does not have a separate state statute that specifically addresses sermorelin by name. The state defers to federal compounding law under the FD&C Act while layering its own pharmacy licensing and practice requirements on top.

SC Board of Pharmacy Licensing

The South Carolina Board of Pharmacy, housed within the Department of Labor, Licensing and Regulation, requires that any pharmacy compounding sterile preparations (sermorelin is typically an injectable peptide reconstituted from lyophilized powder) hold a Sterile Compounding permit in addition to its standard pharmacy license. Requirements include compliance with USP Chapter 797 sterile compounding standards, which govern beyond-use dating, environmental monitoring, and sterility testing.

Patients obtaining sermorelin in South Carolina should confirm that the dispensing pharmacy holds an active SC Board of Pharmacy license and, for injectable preparations, a sterile compounding endorsement. License status can be verified through the SC LLR public license lookup tool.

Prescribing Authority in South Carolina

Under the South Carolina Medical Practice Act (S.C. Code Ann. Title 40, Chapter 47), licensed physicians (MD, DO) hold full prescriptive authority for compounded preparations including sermorelin. Advanced Practice Registered Nurses (APRNs) with prescriptive authority agreements and Physician Assistants (PAs) with supervising physician agreements may also prescribe sermorelin within their scope of practice.

South Carolina does not require a separate state-level permit to prescribe compounded peptides. A valid DEA registration is not required for sermorelin specifically because it is not a controlled substance, though prescribers must still maintain good-faith prescribing practices consistent with the Medical Practice Act.

Telehealth Prescribing in South Carolina

South Carolina law (S.C. Code Ann. Section 40-47-37) permits telehealth prescribing when a valid prescriber-patient relationship has been established. For sermorelin, this generally means at least one documented clinical consultation, review of relevant labs (baseline IGF-1, fasting glucose, thyroid panel), and a documented clinical rationale before the prescription is issued.

The South Carolina Board of Medical Examiners issued guidance in 2021 reinforcing that the standard of care for telehealth prescribing must match in-person standards. A provider who issues sermorelin prescriptions without any history, physical, or laboratory baseline may face licensing scrutiny even if the prescription itself is technically legal.

Clinical Background: What Sermorelin Does and Why Patients Seek It

Sermorelin acetate is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). By binding pituitary GHRH receptors, it stimulates the pulsatile release of endogenous growth hormone (GH) rather than introducing exogenous GH directly. This mechanism is considered lower-risk than direct GH administration because it preserves the pituitary's own negative feedback loop.

IGF-1 as the Primary Monitoring Biomarker

Growth hormone's downstream effects are largely mediated through insulin-like growth factor-1 (IGF-1), produced primarily in the liver. Clinicians measure serum IGF-1 before starting sermorelin and at 90-day intervals during therapy to confirm biological response and avoid supraphysiologic levels. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults recommends using IGF-1 measurements to titrate GH-axis therapies and to assess response (Endocrine Society CPG, J Clin Endocrinol Metab 2019).

A baseline IGF-1 in the lower quartile for age and sex (typically <150 ng/mL in adults over 40) alongside clinical symptoms forms the foundation of a sermorelin prescription that will withstand audit.

Symptoms That Drive Prescription Requests

Adult patients presenting for sermorelin evaluation in South Carolina clinics most often report:

• Fatigue unresponsive to thyroid or testosterone optimization
• Reduced lean muscle mass despite adequate protein intake and resistance training
• Elevated visceral adiposity, particularly in the truncal region
• Sleep architecture disruption, specifically reduced slow-wave sleep where endogenous GH secretion peaks

These are consistent with the symptom cluster described in the Endocrine Society's adult GHD guidelines, though sermorelin is not FDA-approved for GH deficiency specifically. Providers must document medical necessity for any off-label compounded prescription.

Published Evidence Base

A 6-month double-blind placebo-controlled trial by Vittone et al. (N=21, mean age 67) found that sermorelin 2 mcg/kg/day administered subcutaneously produced a statistically significant increase in IGF-1 and lean body mass compared with placebo Vittone J et al., Metabolism 1997, PMID 9121579. Mean IGF-1 rose by 34% from baseline in the active treatment group (P<0.01).

A separate analysis by Walker RF published in the journal Growth Hormone & IGF Research examined the safety profile of sermorelin over 12 months and found no significant adverse effects on fasting glucose, cortisol, or prolactin at standard doses Walker RF, Growth Horm IGF Res 2006, PMID 16428066.

These trials are small by modern standards, and no large randomized controlled trial equivalent to semaglutide's STEP-1 (N=1,961) exists for sermorelin. The evidence base supports biological plausibility and short-term safety but not the level of evidence required for FDA drug approval.

How to Get Sermorelin Legally in South Carolina: Step by Step

Getting a legal sermorelin prescription in South Carolina follows a predictable sequence. Each step matters from both a clinical and a legal standpoint.

Step 1: Establish Care With a Qualified Provider

The prescribing provider must be licensed in South Carolina. This can be an in-person clinic or a telehealth provider with a valid SC prescribing license. Hormone optimization clinics, men's health clinics, anti-aging medicine practices, and some endocrinology or functional medicine offices are the most common points of access.

Verify that the provider is in good standing with the SC Board of Medical Examiners or the Board of Nursing (for APRNs) before sharing personal health information.

Step 2: Complete Required Laboratory Testing

No reputable provider should prescribe sermorelin without baseline labs. The minimum reasonable panel includes:

• Serum IGF-1 (age- and sex-adjusted reference range)
• Fasting insulin and fasting glucose (to rule out insulin resistance, which worsens with supraphysiologic GH activity)
• Comprehensive metabolic panel
• Thyroid panel (TSH, free T4)
• Complete blood count

Some clinicians also order a GH stimulation test (arginine or glucagon stimulation) to document frank GH deficiency, though this is more commonly required for pediatric indications or insurance reimbursement purposes.

Step 3: Receive and Review the Prescription

A valid sermorelin prescription in South Carolina will specify the dose (commonly 200 to 500 mcg subcutaneously at bedtime), frequency, quantity, and the name of the compounding pharmacy. The most common dosing protocol is nightly subcutaneous injection 5 days on, 2 days off to reduce pituitary desensitization.

Patients should receive written instructions for reconstitution (sermorelin typically ships as a lyophilized powder requiring sterile bacteriostatic water), storage (refrigerated at 2 to 8 degrees Celsius after reconstitution), and injection technique.

Step 4: Confirm Pharmacy Licensure

Before filling the prescription, verify the compounding pharmacy:

1. Holds an active South Carolina Board of Pharmacy license (or holds a non-resident pharmacy license issued by SC LLR if located out of state).
2. Holds a sterile compounding endorsement.
3. Can provide a certificate of analysis (CoA) for the batch, confirming identity, potency, and sterility testing.

Purchasing sermorelin from an online vendor that does not require a prescription, does not display pharmacy licensure, or sells it labeled as "research use only" is illegal under federal law and carries significant health risks from unverified purity.

Step 5: Follow-Up and Monitoring

The Endocrine Society guideline cited above recommends checking IGF-1 at 1 to 3 months after starting any GH-axis therapy and adjusting dose to keep IGF-1 in the mid-normal range for age and sex. Monitoring visits also provide the legal documentation that confirms ongoing medical necessity, which matters if the prescription is ever audited.

Risks of Obtaining Sermorelin Outside Legal Channels

The "research chemical" market for peptides is large and largely unregulated. Products sold without a prescription as "for research use only" are not legally intended for human use, carry no sterility guarantee, and often contain inaccurate labeled concentrations. A 2018 analysis of 44 peptide products sold through non-pharmacy online vendors found that 25 of 44 samples (56.8%) failed identity or potency testing, and 8 of 44 (18.2%) tested positive for microbial contamination Thevis M et al., Drug Test Anal 2019, PMID 30548186.

Injecting a contaminated preparation carries the risk of injection-site abscess, systemic infection, and sepsis. The risk is not hypothetical. The FDA issued a safety warning in 2023 regarding bacterially contaminated compounded medications distributed by facilities that did not comply with sterile compounding standards (FDA Safety Communication, 2023).

Patients who obtain sermorelin without a prescription may also face legal exposure, though federal enforcement against individual end-users for non-controlled substances has been historically rare. The prescribing provider and pharmacy take on the primary legal risk under federal misbranding and adulteration statutes.

Comparing Sermorelin to Other GHRH-Axis Peptides in SC

South Carolina residents sometimes ask how sermorelin compares with other growth hormone secretagogues in terms of legal access.

| Peptide | Current Compounding Status | DEA Schedule | Notes | |---|---|---|---| | Sermorelin | Permissible (not on prohibited list) | Not scheduled | Available via 503A Rx | | Tesamorelin | FDA-approved (Egrifta) for HIV lipodystrophy; compounding status complex | Not scheduled | Compounding may be restricted as it copies an approved drug | | Ipamorelin | Category 2 (FDA prohibited for compounding as of guidance updates) | Not scheduled | Avoid; compounding is not legal | | CJC-1295 | Category 2 (FDA prohibited) | Not scheduled | Avoid; compounding is not legal | | MK-677 (Ibutamoren) | Not a peptide; unapproved drug; no legal compounding pathway | Not scheduled | Not legally available |

The table above reflects the regulatory picture as of early 2025. Patients and providers must verify current FDA Bulks List status before prescribing or filling any peptide compound, as the FDA updates category designations on a rolling basis.

What South Carolina Providers Say About Sermorelin Prescribing

The American Academy of Anti-Aging Medicine (A4M) and the American Association of Clinical Endocrinology (AACE) do not have published position statements endorsing sermorelin specifically for age-related GH decline outside of diagnosed GH deficiency. The AACE 2019 consensus on adult GHD states: "The diagnosis of GHD in adults should be based on clinical features, biochemical confirmation, and the exclusion of other causes of the presenting symptoms" (AACE Clinical Practice Guidelines, Endocr Pract 2019). This framing places prescribing responsibility squarely on clinical judgment supported by documented lab findings.

South Carolina physicians in the hormone optimization space generally interpret this to mean that a well-documented low IGF-1 plus symptomatic picture justifies a sermorelin trial, even in the absence of a formal endocrinology workup. That position is defensible under the Medical Practice Act as long as the clinical record reflects the diagnostic reasoning.